bioAffinity Technologies, Inc. has announced a remarkable growth in sales of its CyPath® Lung test, which has increased by more than 100% through the third quarter of 2026 compared to the same period in 2025. This surge in sales highlights the growing clinical adoption of the company’s non-invasive test designed to assess the likelihood of lung cancer in high-risk individuals.
The announcement, made on October 6, 2026, is significant as it underscores the company’s position in the market and its potential for future growth. The rise in sales reflects a broader trend within the healthcare industry towards more accessible and less invasive cancer screening methods, which could reshape patient care and diagnostics.
Company Background
bioAffinity Technologies, Inc. is a Delaware corporation operating in the commercial physical and biological research sector, as classified under the SIC code 8731. The company is publicly traded on the Nasdaq under the ticker symbols BIAF and BIAFW. Established to develop innovative diagnostic tests, bioAffinity focuses on addressing critical health challenges, particularly in cancer detection.
What the Filing Says
According to the recent SEC filing (accession number 0001493152-26-045867), the company stated, "sales of its CyPath® Lung test for lung cancer increased more than 100% through the third quarter of 2026 compared to 2025, reflecting continued growth in clinical adoption of the Company’s noninvasive test for assessing the likelihood of lung cancer in high-risk individuals." This statement emphasizes the successful uptake of their product in the market.
Impact
This increase in sales is likely to affect various stakeholders, including healthcare providers, patients, and investors. For healthcare providers, the growing acceptance of bioAffinity's test may lead to enhanced patient care options. Patients, especially those at high risk for lung cancer, could benefit from earlier detection and intervention. Investors may view this growth positively, as it indicates the company's potential for profitability and expansion in the healthcare market.
What's Next
The filing does not say what happens next. However, the continued success of the CyPath® Lung test could lead to further developments in bioAffinity's product offerings or additional announcements regarding partnerships and market strategies.